Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure

• Status: Completed
• Trial end date: 2021-04-23
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this trial is to investigate the efficacy and safety of continuous intravenous administration of low dose iloprost versus placebo for 72-hours, in 80 patients with COVID-19 suffering from respiratory failure. The study hypothesis is that iloprost may be beneficial as an endothelial rescue treatment as it is anticipated to deactivate the endothelium and restore vascular integrity in COVID-19 patients suffering from respiratory failure caused by endothelial breakdown, ultimately improving survival. Given that the pulmonary system, apart from the brain, is the most highly vascularized vital organ in the body, extensive endothelial damage is a central feature of acute respiratory distress syndrome (ARDS) with respiratory failure being the rationale for the current study COMBAT-COVID-19.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pär Johansson
• Treatments: Iloprost

Criteria

Inclusion Criteria:

• Adult intensive care patients (aged 18 years or above)

• Confirmed COVID-19 infection

• Need for mechanical ventilation (< 72 hours at time of screening)

• Soluble thrombomodulin (sTM) ≥ 4 ng/mL

Exclusion Criteria:

• Withdrawal from active therapy

• Pregnancy (non-pregnancy confirmed by patient being postmenopausal (age 60 or above) or having a negative urine- or plasma-hCG)

• Known hypersensitivity to iloprost or to any of the other ingredients.

• Previously included in this trial or a prostacyclin trial within 30 days

• Consent cannot be obtained

• Life-threatening bleeding defined by the treating physician

• Known severe heart failure (NYHA class IV)

• Suspected acute coronary syndrome